A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|16|2749-2756

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.16, 2015-08, pp. : 2749-2756

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Multitargeted Kinase Inhibition in Metastatic Differentiated Radioiodine-Refractory Thyroid Cancer: A Look at New Therapeutic Options for a Rare Disease

By  

Oncology Research and Treatment, Vol. 39, Iss. 9, 2016-08 ,pp. : 548-552

Karger

Access to resources Recommend Favorite

The Evolving Use of Radioiodine Therapy in Differentiated Thyroid Cancer

By  

Oncology, Vol. 88, Iss. 4, 2014-12 ,pp. : 247-256

Karger

Access to resources Recommend Favorite

Effects of radioiodine treatment for differentiated thyroid cancer on testis function

By  

CLINICAL ENDOCRINOLOGY, Vol. 82, Iss. 2, 2015-02 ,pp. : 295-299

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of mathematical models for red marrow and blood absorbed dose estimation in the radioiodine treatment of advanced differentiated thyroid carcinoma

By Miranti A   Giostra A   Richetta E   Gino E   Pellerito R E   Stasi M  

Physics in Medicine and Biology, Vol. 60, Iss. 3, 2015-02 ,pp. : 1141-1157

IOP Publishing

Access to resources Recommend Favorite

Clinical outcomes of carbon ion radiotherapy for locally advanced adenocarcinoma of the uterine cervix in phase 1/2 clinical trial (protocol 9704)

By  

CANCER, Vol. 120, Iss. 11, 2014-06 ,pp. : 1663-1669

John Wiley & Sons Inc

Access to resources Recommend Favorite